Could a gel prevent anal cancer in HIV patients?
NCT ID NCT05334004
First seen Feb 11, 2026 · Last updated Apr 28, 2026 · Updated 11 times
Summary
This early-stage study tests the safety of a gel containing two HIV drugs (lopinavir/ritonavir) applied inside the anus. It involves 21 adults with HIV who have high-grade anal lesions (precancerous cells). The goal is to find a safe dose and see if the gel can shrink or eliminate these lesions, potentially preventing anal cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE ANAL INTRAEPITHELIAL NEOPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UW Digestive Health Center Anoscopy Clinic
RECRUITINGMadison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.